Preparation and Characterization of Folate Targeting Magnetic Nanomedicine Loaded with Cisplatin

We used Aldehyde sodium alginate (ASA) as modifier to improve surfactivity and stability of magnetic nanoparticles, and folate acid (FA) as targeting molecule. Fe3O4 nanoparticles were prepared by chemical coprecipitation method. FA was activated and coupled with diaminopolyethylene glycol (NH2-PEG-NH2). ASA was combined with Fe3O4 nanoparticles, and FA-PEG was connected with ASA by Schiff's base formation. Then Cl- in cisplatin was replaced by hydroxyl group in ASA, and FA-and ASA-modified cisplatin-loaded magnetic nanomedicine (CDDP-FA-ASA-MNPs) was prepared. This nanomedicine was characterized by transmission electron microscopy, dynamic lighterring scattering, phase analysis light scattering and vibrating sample magnetometer. The uptake of magnetic nanomedicine by nasopharyngeal and laryngeal carcinoma cells with folate receptor positive or negative expression were observed by Prussian blue iron stain and transmission electron microscopy. We found that CDDP-FA-ASA-MNPs have good water-solubility and stability. Mean diameter of Fe3O4 core was 8.17 +/- 0.24 nm, hydrodynamic diameters was 110.90 +/- 1.70 nm, and zeta potential was -26.45 +/- 1.26 mV. Maximum saturation magnetization was 22.20 emu/g. CDDP encapsulation efficiency was 49.05 +/- 1.58% (mg/mg), and drug loading property was 14.31 +/- 0.49% (mg/mg). In vitro, CDDP-FA-ASA-MNPs were selectively taken up by HNE-1 cells and Hep-2 cells, which express folate receptor positively.